Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 140 days in a single patient, to conclusively describe reinfection with a new strain harboring the spike variant D614G. With antibody and B cell analytics, we show correlates of adaptive immunity, including a differential response to D614G. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.
Article activity feed
-
SciScore for 10.1101/2020.09.22.20192443: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Informed consent was waived for use of residual samples and population clinical data (STUDY2020000143). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 25 Serological testing used enzyme-linked immunosorbent assay (ELISA) for anti-spike, anti-RBD, and anti-N IgG, IgM and IgA antibodies, as well as a functional assay for antibodies that block binding of RBD to an ACE2 fusion protein. anti-spike, anti-RBD,suggested: Noneanti-N IgGsuggested: NoneIgAsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. …
SciScore for 10.1101/2020.09.22.20192443: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Informed consent was waived for use of residual samples and population clinical data (STUDY2020000143). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources 25 Serological testing used enzyme-linked immunosorbent assay (ELISA) for anti-spike, anti-RBD, and anti-N IgG, IgM and IgA antibodies, as well as a functional assay for antibodies that block binding of RBD to an ACE2 fusion protein. anti-spike, anti-RBD,suggested: Noneanti-N IgGsuggested: NoneIgAsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
